Eir Ventures portfolio company, Pretzel Therapeutics, announces USD 72,5M series A financing

Pretzel is developing treatments to address the genetic roots of mitochondrial dysfunction.

Pretzel was founded by some of the world’s foremost academics in mitochondrial biology, and we benefit from the leadership of accomplished experts in drug discovery, drug development, and company formation. The name is inspired by the focal point of our science, the mitochondrion, whose highly folded inner membrane is one of many fascinating features that make it unlike any other organelle in the body.

Read the full Press Release here